

---

**From:** Paul Finnegan [REDACTED] >  
**Sent:** Wednesday, September 2, 2015 2:12 PM  
**To:** [REDACTED]  
**Cc:** Jeffrey Port  
**Subject:** Angiocrine Bioscience "numbers" requested  
**Attachments:** Angiocrine - Capitalization Table (2015.7.10) Summary v150901.pdf; Angiocrine Comp Analysis\_Trout Capital LLC-Angiocrine\_v150818 0634 PFCGD FINAL.xlsx; Angiocrine Bioscience Inc\_3.25 year Forecast\_\$5M+\$25M v150902 0625.xlsx

Dear Jeffrey,

Attached are the 3 deliverables you requested when we met you at your residence in NYC earlier this summer:

- (1) Cap Table Summary (updated since our meeting)
- (2) Comparator Table to support assumed valuation for Series B institutional
  - a. Summary tab are the assumptions we discussed during our meeting
  - b. 2nd and 3rd tabs provide data of comparator companies (pre-money Series B, IPO if applicable) for the assumptions
- (3) 3 year P&L (financial projection for cumulative \$30M raised over the next 2 upcoming quarters)
  - a. Spend is geared to a potential \$5M from high-net-worth individuals investment by Nov 1st 2015
  - b. Another assumption is availability of the first tranche from \$25M Series B institutional round by Apr 1st 2016
  - c. As you suggested, we continue to believe that \$30M over 3.25 years provides adequate funds to reach an inflection/exit point and still have "dry powder" for contingencies and for the negotiation period if and at the time we achieve positive human clinical proof of concept

I am also sending the email & attachments to Lesley in case you prefer she prints out the attached for you or to another email address you prefer.

Since we met, we have made progress on: (1) refining manufacturing; (2) clinical trial details; (3) preparation for institutional investor due diligence; and (4) begun presenting to institutional investors [full swing after Labor Day].

Please do not hesitate to contact me if you have any questions.

Best regards, Paul

Paul W. Finnegan, MD, MBA

Chief Executive Officer

Angiocrine Bioscience, Inc.

3570 Carmel Mountain Rd, Suite 200,

San Diego, CA 92130

Angiocrine Bioscience Research

Weill Cornell Medical College, Medical Research Building A-335

1300 York Avenue,

New York, NY 10065